Key result
Regular aspirin use prior to potentially curative resection for non-small cell lung cancer was associated with a >5% increase in long-term survival (p=0.05).
Why the study?
Does aspirin therapy improve long-term survival in patients undergoing resection for non-small cell lung cancer?
Cohort (n=1,765)
Does aspirin therapy improve long-term survival in patients undergoing resection for non-small cell lung cancer?
p-value: p=0.05
Adjuvant aspirin post-resection for non-small cell lung cancer is associated with a significant increase in long-term survival.
No takes yet. Share an insight, caveat, or question.
May support aspirin for CV prevention after NSCLC resection; leaves open antimetastatic effects pending randomized trials.
Fontaine et al. (2010) conducted a cohort in Non-small cell lung cancer (n=1,765). Aspirin vs. Non-users was evaluated on Long-term survival (p=0.05). Regular aspirin use prior to potentially curative resection for non-small cell lung cancer was associated with a >5% increase in long-term survival (p=0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: